- Open
- 0.13
- High
- 0.13
- Low
- 0.11
- Close
- 0.11
- Change
- -0.00 (-4.35%)
- Volume
- 24,361,428
| 29 Sept 2026 | 07:00:06 | New Analysis Identifies Major AUD Breakthrough |
| 3 Sept 2026 | 07:00:02 | Vital Patent milestone achieved– SVN 114 |
| 25 Aug 2026 | 07:00:03 | Solvonis Raises £1.3 Million |
| 11 Aug 2026 | 07:00:05 | Solvonis to Present at WTR Conference |
| 6 Aug 2026 | 07:00:02 | SVN-015 Advances into Further NIDA-Funded Studies |
| 1 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 May 2026 | Annual Report for the year ended 31 December 2025 | |
| 7 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Solvonis Therapeutics PLC is a biopharmaceutical company focused on developing small-molecule therapeutics for central nervous system (CNS) disorders, particularly in the areas of addiction and psychiatry. The company has a pipeline that includes two programs for Alcohol Use Disorder (AUD): SVN-001, targeting severe AUD in the UK and EU, and SVN-002, aimed at moderate-to-severe AUD in the U.S. and other markets. Solvonis operates through a model that combines later-stage clinical assets with discovery-stage innovation, primarily in the UK and U.S. markets.
| 29 Sept 2026 | 07:00:06 | New Analysis Identifies Major AUD Breakthrough |
| 3 Sept 2026 | 07:00:02 | Vital Patent milestone achieved– SVN 114 |
| 25 Aug 2026 | 07:00:03 | Solvonis Raises £1.3 Million |
| 11 Aug 2026 | 07:00:05 | Solvonis to Present at WTR Conference |
| 6 Aug 2026 | 07:00:02 | SVN-015 Advances into Further NIDA-Funded Studies |
| 1 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 May 2026 | Annual Report for the year ended 31 December 2025 | |
| 7 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Solvonis Therapeutics PLC is a biopharmaceutical company focused on developing small-molecule therapeutics for central nervous system (CNS) disorders, particularly in the areas of addiction and psychiatry. The company has a pipeline that includes two programs for Alcohol Use Disorder (AUD): SVN-001, targeting severe AUD in the UK and EU, and SVN-002, aimed at moderate-to-severe AUD in the U.S. and other markets. Solvonis operates through a model that combines later-stage clinical assets with discovery-stage innovation, primarily in the UK and U.S. markets.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £43m | -0.2% | |
| £11m | -0.1% | |
SVNSSolvonis Therapeutics PLC | £8m | -0.7% |
| £4m | +0.0% | |
| £3m | -0.9% | |
| £730k | -0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £43m | -0.2% | |
| £11m | -0.1% | |
SVNSSolvonis Therapeutics PLC | £8m | -0.7% |
| £4m | +0.0% | |
| £3m | -0.9% | |
| £730k | -0.2% |
